Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.

McCrystal, M R; Evans, B D; Harvey, V J; Thompson, P I; Porter, D J; Baguley, B C

McCrystal, M R; Evans, B D; Harvey, V J; Thompson, P I; Porter, D J; Baguley, B C.

Affiliation

McCrystal MR; Department of Clinical Oncology, Auckland Hospital, New Zealand. meganb@ahsl.co.nz

Cancer Chemother Pharmacol ; 44(1): 39-44, 1999.

Article in En | MEDLINE | ID: mdl-10367747

Subject(s)

Acridines/adverse effects; Antineoplastic Agents/adverse effects; Neoplasms/drug therapy; Acridines/administration & dosage; Adult; Aged; Antineoplastic Agents/administration & dosage; Dose-Response Relationship, Drug; Facial Pain/chemically induced; Female; Humans; Infusions, Intravenous; Male; Middle Aged

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Acridines / Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Cancer Chemother Pharmacol Year: 1999 Document type: Article Affiliation country: New Zealand Country of publication: Germany

Search on Google

Add to My VHL

XML

PubMed Links